Skip to main content
Top
Published in: Supportive Care in Cancer 4/2016

01-04-2016 | Original Article

A randomised trial of the cool pad pillow topper versus standard care for sleep disturbance and hot flushes in women on endocrine therapy for breast cancer

Authors: R. Marshall-McKenna, A. Morrison, L. Stirling, C. Hutchison, A. M. Rice, C. Hewitt, L. Paul, M. Rodger, I. R. Macpherson, E. McCartney

Published in: Supportive Care in Cancer | Issue 4/2016

Login to get access

Abstract

Purpose

Quality of life in women receiving adjuvant endocrine therapy for breast cancer (BC) may be impaired by hot flushes and night sweats. The cool pad pillow topper (CPPT) is a commercial product, promoted to improve quality of sleep disrupted by hot flushes. This study aimed to identify if the CPPT reduces severity of sleep disturbance by minimising effects of hot flushes.

Methods

This randomised phase II trial, recruited women with BC, on adjuvant endocrine therapy, experiencing hot flushes and insomnia. Participants were randomised (stratified by baseline sleep efficiency score (SES) and menopausal status) to the intervention arm (CPPT + standard care) or control arm (standard care). Participants completed Hospital Anxiety and Depression Scale and Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaires and fortnightly sleep/hot flush diaries (where responses were averaged over 2-week periods). The primary endpoint was change in average SES from −2 to 0 weeks to 2 to 4 weeks.

Results

Seventy-four pre- (68.9 %) and post-menopausal (31.1 %) women were recruited. Median age was 49.5 years. Endocrine therapies included tamoxifen (93.2 %). Median SES at weeks 2 to 4 improved in both arms but the increase on the intervention arm was almost twice that on the control arm (p = 0.024). There were significantly greater reductions in hot flushes and HADS depression in the intervention arm (p = 0.09 and p = 0.036, respectively). There were no significant differences in FACT-B or HADS anxiety.

Conclusion

This study supports the use of the CPPT as an aid to reduce sleep disturbance and the frequency/severity of hot flushes.
Literature
1.
go back to reference Lifetime risk was calculated using 2010 data for females and 2008–2010 data for males by the Statistical Information Team at Cancer Research UK, 2012. Available at: Lifetime risk was calculated using 2010 data for females and 2008–2010 data for males by the Statistical Information Team at Cancer Research UK, 2012. Available at:
3.
go back to reference Fenlon DR, Corner JL, Haviland J (2009) Menopausal hot flushes after breast cancer. Eur J Cancer Care 18:140–148CrossRef Fenlon DR, Corner JL, Haviland J (2009) Menopausal hot flushes after breast cancer. Eur J Cancer Care 18:140–148CrossRef
4.
go back to reference McCowan C, Tompson AM (2012) The importance of nonpharmacogenetic factors in endocrine therapy. Pharmacogenomics 13(6):721–728CrossRefPubMed McCowan C, Tompson AM (2012) The importance of nonpharmacogenetic factors in endocrine therapy. Pharmacogenomics 13(6):721–728CrossRefPubMed
5.
go back to reference MCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, Fahey TP (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. BJC 99:1763–1768CrossRef MCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, Fahey TP (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. BJC 99:1763–1768CrossRef
6.
go back to reference Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai W-Y, Fehrenbacher L, Lin Gomez S, Miles S, Neugut AI (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8769 early-stage breast cancer patients. J Clin Oncol 28(27):4120–4128PubMedCentralCrossRefPubMed Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai W-Y, Fehrenbacher L, Lin Gomez S, Miles S, Neugut AI (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8769 early-stage breast cancer patients. J Clin Oncol 28(27):4120–4128PubMedCentralCrossRefPubMed
7.
go back to reference Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C (2013) Cohort study adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. BJC 108:1515–1524PubMedCentralCrossRefPubMed Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C (2013) Cohort study adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. BJC 108:1515–1524PubMedCentralCrossRefPubMed
8.
go back to reference Fenlon DR, Rogers AE (2007) The experience of hot flushes after breast cancer. Cancer Nurs 30(4):E19–E26CrossRefPubMed Fenlon DR, Rogers AE (2007) The experience of hot flushes after breast cancer. Cancer Nurs 30(4):E19–E26CrossRefPubMed
9.
go back to reference Lammerink EAG, de Bock GH, Schroder CP, Mourits MJE (2012) The management of menopausal symptoms in breast cancer survivors: a case-based approach. Maturitas 73:265–268CrossRefPubMed Lammerink EAG, de Bock GH, Schroder CP, Mourits MJE (2012) The management of menopausal symptoms in breast cancer survivors: a case-based approach. Maturitas 73:265–268CrossRefPubMed
10.
11.
go back to reference Hunter MS, Grunfeld EA, Mittal S et al (2004) Menopausal symptoms in women with breast cancer: prevalence and treatment preferences. Psycho-Oncology 13:769–778CrossRefPubMed Hunter MS, Grunfeld EA, Mittal S et al (2004) Menopausal symptoms in women with breast cancer: prevalence and treatment preferences. Psycho-Oncology 13:769–778CrossRefPubMed
12.
go back to reference Gupta P, Sturdee D, Pallin S, Majumder K, Fear R, Marshall T, Paterson I (2006) Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life. Climacteric 9:49–58CrossRefPubMed Gupta P, Sturdee D, Pallin S, Majumder K, Fear R, Marshall T, Paterson I (2006) Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life. Climacteric 9:49–58CrossRefPubMed
13.
go back to reference Chilcot J, Norton S, Hunter MS (2014) Cognitive behaviour therapy for menopausal symptoms following breast cancer treatment: who benefits and how does it work? Maturitas 78:56–61CrossRefPubMed Chilcot J, Norton S, Hunter MS (2014) Cognitive behaviour therapy for menopausal symptoms following breast cancer treatment: who benefits and how does it work? Maturitas 78:56–61CrossRefPubMed
14.
go back to reference Savard J, Davidson JR, Ivers H et al (2004) The association between nocturnal hot flashes and sleep in breast cancer survivors. J Pain Symptom Manag 27:513–522CrossRef Savard J, Davidson JR, Ivers H et al (2004) The association between nocturnal hot flashes and sleep in breast cancer survivors. J Pain Symptom Manag 27:513–522CrossRef
15.
go back to reference Pinto AC, de Azambuja E (2011) Improving quality of life after breast cancer dealing with symptoms. Maturitas 70:343–348CrossRefPubMed Pinto AC, de Azambuja E (2011) Improving quality of life after breast cancer dealing with symptoms. Maturitas 70:343–348CrossRefPubMed
16.
go back to reference Rendall MJ, Simonds LM, Hunter MS (2008) The hot flush beliefs scale: a tool for assessing thoughts and beliefs associated with the experience of menopausal hot flushes and night sweats. Maturitas 60(2):158–169CrossRefPubMed Rendall MJ, Simonds LM, Hunter MS (2008) The hot flush beliefs scale: a tool for assessing thoughts and beliefs associated with the experience of menopausal hot flushes and night sweats. Maturitas 60(2):158–169CrossRefPubMed
18.
go back to reference Holmberg L, Anderson H (2004) HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped. Lancet 363:453–455CrossRefPubMed Holmberg L, Anderson H (2004) HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped. Lancet 363:453–455CrossRefPubMed
19.
go back to reference Rada G, Capurro D, Pantoja T et al (2010) Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev 9, CD004923PubMed Rada G, Capurro D, Pantoja T et al (2010) Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev 9, CD004923PubMed
20.
go back to reference Othman AH, Zaky AH (2014) Management of hot flushes in breast cancer survivors: comparison between stellate ganglion block and pregabalin. Pain Med 15(3):410–417CrossRefPubMed Othman AH, Zaky AH (2014) Management of hot flushes in breast cancer survivors: comparison between stellate ganglion block and pregabalin. Pain Med 15(3):410–417CrossRefPubMed
21.
go back to reference Cruickshank S, Hume A (2014) The experience of providing support about menopausal symptoms to women with breast cancer. Eur J Oncol Nurs 18:110–117CrossRefPubMed Cruickshank S, Hume A (2014) The experience of providing support about menopausal symptoms to women with breast cancer. Eur J Oncol Nurs 18:110–117CrossRefPubMed
22.
go back to reference Fritz H, Seely D, McGowan J et al (2014) Black cohosh and breast cancer: a systematic review. ICT 13(1):12–29 Fritz H, Seely D, McGowan J et al (2014) Black cohosh and breast cancer: a systematic review. ICT 13(1):12–29
23.
24.
go back to reference Bokmand S, Flyger H (2013) Acupuncture relieves menopausal discomfort in breast cancer patients: a prospective, double blinded, randomized study. Breast 22:320–323CrossRefPubMed Bokmand S, Flyger H (2013) Acupuncture relieves menopausal discomfort in breast cancer patients: a prospective, double blinded, randomized study. Breast 22:320–323CrossRefPubMed
25.
go back to reference Walker EM, Rodriguez AI, Kohn B et al (2010) Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol 28(4):634–640CrossRefPubMed Walker EM, Rodriguez AI, Kohn B et al (2010) Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol 28(4):634–640CrossRefPubMed
26.
go back to reference Carpenter JS, Neal JG, Payne J, Kimmick G, Storniolo AM (2007) Cognitive-behavioral intervention for hot flashes. Oncol Nurs Forum 34(1):37CrossRefPubMed Carpenter JS, Neal JG, Payne J, Kimmick G, Storniolo AM (2007) Cognitive-behavioral intervention for hot flashes. Oncol Nurs Forum 34(1):37CrossRefPubMed
27.
go back to reference Hunter MS, Coverntry S, Hamed H, Fentiman I, Grunfeld EA (2009) Evaluation of a group cognitive behavioural intervention for women suffering from menopausal symptoms following breast cancer treatment. Psycho-Oncology 18:560–563CrossRefPubMed Hunter MS, Coverntry S, Hamed H, Fentiman I, Grunfeld EA (2009) Evaluation of a group cognitive behavioural intervention for women suffering from menopausal symptoms following breast cancer treatment. Psycho-Oncology 18:560–563CrossRefPubMed
28.
go back to reference Hunter MS, Liao KL (1995) A psychological analysis of menopausal hot flushes. Br J Clin Psychol 34:589–599CrossRefPubMed Hunter MS, Liao KL (1995) A psychological analysis of menopausal hot flushes. Br J Clin Psychol 34:589–599CrossRefPubMed
29.
go back to reference Hunter M (1992) The Women’s Health Questionnaire: a measure of mid-aged women’s perceptions of emotional and physical health. Psychol Health 7:45–54CrossRef Hunter M (1992) The Women’s Health Questionnaire: a measure of mid-aged women’s perceptions of emotional and physical health. Psychol Health 7:45–54CrossRef
30.
go back to reference Morgan A, Fenlon DR (2013) Is it me or is it hot in here? A plea for more research into hot flushes. Clin Oncol 25:681–683CrossRef Morgan A, Fenlon DR (2013) Is it me or is it hot in here? A plea for more research into hot flushes. Clin Oncol 25:681–683CrossRef
31.
go back to reference Elspie CA (1991) The psychological treatment of insomnia. Wiley, Chichester Elspie CA (1991) The psychological treatment of insomnia. Wiley, Chichester
32.
go back to reference Langford DJ, Lee K, Miaskowski C (2012) Sleep disturbance interventions in oncology patients and family caregivers: a comprehensive review and meta-analysis. Sleep Med Rev 16:397–414CrossRefPubMed Langford DJ, Lee K, Miaskowski C (2012) Sleep disturbance interventions in oncology patients and family caregivers: a comprehensive review and meta-analysis. Sleep Med Rev 16:397–414CrossRefPubMed
33.
go back to reference Bastien CH, Vallieres A, Morin CM (2001) Validation of the insomnia severity index as an outcome measure for insomnia research. Sleep Med 2(4):297–307CrossRefPubMed Bastien CH, Vallieres A, Morin CM (2001) Validation of the insomnia severity index as an outcome measure for insomnia research. Sleep Med 2(4):297–307CrossRefPubMed
34.
go back to reference Elspie CA, Fleming L, Cassidy J et al (2008) Randomized controlled clinical effectiveness trial of cognitive behaviour therapy compared with treatment as usual for persistent insomnia in patients with cancer. J Clin Oncol 26(28):4651–4658CrossRef Elspie CA, Fleming L, Cassidy J et al (2008) Randomized controlled clinical effectiveness trial of cognitive behaviour therapy compared with treatment as usual for persistent insomnia in patients with cancer. J Clin Oncol 26(28):4651–4658CrossRef
35.
go back to reference Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H (2001) Methodologic lessons learned from hot flash studies. J Clin Oncol 19(23):4280–4290PubMed Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H (2001) Methodologic lessons learned from hot flash studies. J Clin Oncol 19(23):4280–4290PubMed
36.
go back to reference Finck G, Barton DL, Loprinzi CL, Quella SK, Sloan JA (1998) Definitions of hot flashes in breast cancer survivors. J Pain Symptom Manag 16(5):327–333CrossRef Finck G, Barton DL, Loprinzi CL, Quella SK, Sloan JA (1998) Definitions of hot flashes in breast cancer survivors. J Pain Symptom Manag 16(5):327–333CrossRef
38.
go back to reference Reddy SY, Warner B, Guttuso T Jr et al (2006) Gabapentin, estrogen and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 108:41–48CrossRefPubMed Reddy SY, Warner B, Guttuso T Jr et al (2006) Gabapentin, estrogen and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 108:41–48CrossRefPubMed
39.
go back to reference Zigmond AS, Snaith RP (1983) The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67:361–370CrossRefPubMed Zigmond AS, Snaith RP (1983) The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67:361–370CrossRefPubMed
40.
go back to reference Brady MJ, Cella DF, Mo F et al (1997) Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 15(3):974–986PubMed Brady MJ, Cella DF, Mo F et al (1997) Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 15(3):974–986PubMed
41.
go back to reference Carpenter JS, Storniolo AM, Johns S et al (2007) Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. Oncologist 12:124–135CrossRefPubMed Carpenter JS, Storniolo AM, Johns S et al (2007) Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. Oncologist 12:124–135CrossRefPubMed
42.
go back to reference Frisk J, Kallstrom AC, Wall N, Fredrikson M, Hammar M (2012) Acupuncture improves health-related quality-of-life (HRQoL) and sleep in women with breast cancer and hot flushes. Support Care Cancer 20:715–724CrossRefPubMed Frisk J, Kallstrom AC, Wall N, Fredrikson M, Hammar M (2012) Acupuncture improves health-related quality-of-life (HRQoL) and sleep in women with breast cancer and hot flushes. Support Care Cancer 20:715–724CrossRefPubMed
43.
go back to reference Fenlon DR, Corner JL, Haviland JS (2008) A randomized controlled trial of relaxation training to reduce hot flashes in women with primary breast cancer. J Pain Symptom Manag 35(4):397–405CrossRef Fenlon DR, Corner JL, Haviland JS (2008) A randomized controlled trial of relaxation training to reduce hot flashes in women with primary breast cancer. J Pain Symptom Manag 35(4):397–405CrossRef
44.
go back to reference Duijts SFA, Beurden M, Oldenburg HAS, Hunter MS et al (2012) Efficacy of cognitive behavioural therapy and physical exercise in alleviating treatment-induce menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol 30(33):4124–4133CrossRefPubMed Duijts SFA, Beurden M, Oldenburg HAS, Hunter MS et al (2012) Efficacy of cognitive behavioural therapy and physical exercise in alleviating treatment-induce menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol 30(33):4124–4133CrossRefPubMed
45.
go back to reference Palmer JL, Trotter T, Joy AA, Carlson LE (2008) Cognitive effects of tamoxifen in pre-menopausal women with breast cancer compared to healthy controls. J Cancer Surviv 2(4):275–282CrossRefPubMed Palmer JL, Trotter T, Joy AA, Carlson LE (2008) Cognitive effects of tamoxifen in pre-menopausal women with breast cancer compared to healthy controls. J Cancer Surviv 2(4):275–282CrossRefPubMed
Metadata
Title
A randomised trial of the cool pad pillow topper versus standard care for sleep disturbance and hot flushes in women on endocrine therapy for breast cancer
Authors
R. Marshall-McKenna
A. Morrison
L. Stirling
C. Hutchison
A. M. Rice
C. Hewitt
L. Paul
M. Rodger
I. R. Macpherson
E. McCartney
Publication date
01-04-2016
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 4/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-015-2967-3

Other articles of this Issue 4/2016

Supportive Care in Cancer 4/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine